Victor Shue Chung Fung

Victor Shue Chung Fung

Auto-generated profile, based on publicly available information

Victor Shue Chung Fung

Movement Disorders Unit, Department of Neurology Westmead Hospital Sydney NSW Australia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Movement Disorders
Verified
Journal Article
Open access
SJStefanie T. Jost
Stefanie T. Jost
MKMarie‐Ann Kaldenbach
Marie‐Ann Kaldenbach
Angelo AntoniniAngelo Antonini
Angelo Antonini
PMPablo Martinez‐Martin
Pablo Martinez‐Martin
LTLars Timmermann
Lars Timmermann
TGthe International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group
the International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group
Background: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.Objectives: To update LED conversion formulae based on a systematic review.Methods: The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.Results: The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.Conclusions: The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

18 October 2012 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
SKSamuel D. Kim
Samuel D. Kim
NANatalie E. Allen
Natalie E. Allen
CCColleen G. Canning
Colleen G. Canning
VFVictor S. C. Fung
Victor S. C. Fung

4 March 2022 in Science Advances
Verified
Journal Article
Open access
ISIgor Stevanovski
Igor Stevanovski
SCSanjog R. Chintalaphani
Sanjog R. Chintalaphani
HGHasindu Gamaarachchi
Hasindu Gamaarachchi
JFJames M. Ferguson
James M. Ferguson
SPSandy Pineda
Sandy Pineda
IDIra W. Deveson
Ira W. Deveson
More than 50 neurological and neuromuscular diseases are caused by short tandem repeat (STR) expansions, with 37 different genes implicated to date. We describe the use of programmable targeted long-read sequencing with Oxford Nanopore’s ReadUntil function for parallel genotyping of all known neuropathogenic STRs in a single assay. Our approach enables accurate, haplotype-resolved assembly and DNA methylation profiling of STR sites, from a list of predetermined candidates. This correctly diagnoses all individuals in a small cohort ( n = 37) including patients with various neurogenetic diseases ( n = 25). Targeted long-read sequencing solves large and complex STR expansions that confound established molecular tests and short-read sequencing and identifies noncanonical STR motif conformations and internal sequence interruptions. We observe a diversity of STR alleles of known and unknown pathogenicity, suggesting that long-read sequencing will redefine the genetic landscape of repeat disorders. Last, we show how the inclusion of pharmacogenomic genes as secondary ReadUntil targets can further inform patient care.

15 July 2010 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
NANatalie E. Allen
Natalie E. Allen
CCColleen G. Canning
Colleen G. Canning
CSCatherine Sherrington
Catherine Sherrington
SLStephen Lord
Stephen Lord
MLMark D. Latt
Mark D. Latt
VFVictor S.C. Fung
Victor S.C. Fung

6 May 2025 in Movement Disorders
Verified
Journal Article
Open access
AAAlberto Albanese
Alberto Albanese
KBKailash P. Bhatia
Kailash P. Bhatia
VFVictor S.C. Fung
Victor S.C. Fung
MHMark Hallett
Mark Hallett
JJJoseph Jankovic
Joseph Jankovic
HJH.A. Jinnah
H.A. Jinnah
Dystonia is a movement disorder with varied clinical features and diverse etiologies. Here we present a revision of the 2013 consensus definition and classification of dystonia in light of subsequent publications and experience with its application during the last decade. A panel of movement disorder specialists with expertise in dystonia reviewed the original document and proposed some revision. There was broad consensus to retain the definition of dystonia with only minor clarifications to the wording. Dystonia is defined as a movement disorder characterized by sustained or intermittent abnormal movements, postures, or both. Dystonic movements and postures are typically patterned and repetitive and may be tremulous or jerky. They are often initiated or worsened by voluntary action and frequently associated with overflow movements. The two‐axis structure for classification of the many different presentations of dystonia was also retained, with some revision. Axis I summarizes key clinical characteristics of dystonia, including age at onset, family history, body distribution, temporal dimensions, phenomenology, and whether dystonia is isolated or combined with other neurological or medical problems. Axis II organizes information regarding its etiological basis, including genetic, acquired, and anatomical, and common disease mechanisms. This consensus provides an update to the original definition and classification of dystonia with the aim of facilitating its clinical recognition and management. The revision retains the essence of the original proposal and aims particularly to provide a structure facilitating a uniform implementation. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

26 August 2023 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
JAJason L. Aldred
Jason L. Aldred
EFEric Freire-Alvarez
Eric Freire-Alvarez
AAAlexander V. Amelin
Alexander V. Amelin
Angelo AntoniniAngelo Antonini
Angelo Antonini
BBBruno Bergmans
Bruno Bergmans
VFVictor S. C. Fung
Victor S. C. Fung
Introduction Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) with a single infusion site. The efficacy and safety of foslevodopa/foscarbidopa versus oral immediate-release LD/CD was previously demonstrated in patients with PD in a 12-week, randomized, double-blind, phase 3 trial (NCT04380142). We report the results of a separate 52-week, open-label, phase 3 registrational trial (NCT03781167) that evaluated the safety/tolerability and efficacy of 24-hour/day foslevodopa/foscarbidopa CSCI in patients with advanced PD. Methods Male and female patients with levodopa-responsive PD and ≥ 2.5 hours of “Off” time/day received 24-hour/day foslevodopa/foscarbidopa CSCI at individually optimized therapeutic doses (approximately 700–4250 mg of LD per 24 hours) for 52 weeks. The primary endpoint was safety/tolerability. Secondary endpoints included changes from baseline in normalized “Off” and “On” time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Parkinson’s Disease Sleep Scale–2 (PDSS-2), 39-item Parkinson’s Disease Questionnaire (PDQ-39), and EuroQol 5-dimension questionnaire (EQ-5D-5L). Results Of 244 enrolled patients, 107 discontinued, and 137 completed treatment. Infusion site events were the most common adverse events (AEs). AEs were mostly nonserious (25.8% of patients reported serious AEs) and mild/moderate in severity. At week 52, “On” time without troublesome dyskinesia and “Off” time were improved from baseline (mean [standard deviation (SD)] change in normalized “On” time without troublesome dyskinesia, 3.8 [3.3] hours; normalized “Off” time, −3.5 [3.1] hours). The percentage of patients experiencing morning akinesia dropped from 77.7% at baseline to 27.8% at week 52. Sleep quality (PDSS-2) and quality of life (PDQ-39 and EQ-5D-5L) also improved. Conclusion Foslevodopa/foscarbidopa has the potential to provide a safe and efficacious, individualized, 24-hour/day, nonsurgical alternative for patients with PD. Trial Registration Number ClinicalTrials.gov identifier NCT03781167.